These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 9669386)

  • 21. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview.
    Warner RR; O'dorisio TM
    Semin Nucl Med; 2002 Apr; 32(2):79-83. PubMed ID: 11965602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.
    Baudin E; Lumbroso J; Schlumberger M; Leclere J; Giammarile F; Gardet P; Roche A; Travagli JP; Parmentier C
    J Nucl Med; 1996 Jun; 37(6):912-6. PubMed ID: 8683310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.
    Shi W; Johnston CF; Buchanan KD; Ferguson WR; Laird JD; Crothers JG; McIlrath EM
    QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy.
    Lebtahi R; Cadiot G; Delahaye N; Genin R; Daou D; Peker MC; Chosidow D; Faraggi M; Mignon M; Le Guludec D
    J Nucl Med; 1999 Oct; 40(10):1602-8. PubMed ID: 10520698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
    Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
    J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma.
    Kosowicz J; Mikołajczak R; Czepczyński R; Ziemnicka K; Gryczyńska M; Sowiński J
    Cancer Biother Radiopharm; 2007 Oct; 22(5):613-28. PubMed ID: 17979564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Somatostatin receptor imaging for neuroendocrine tumors.
    de Herder WW; Kwekkeboom DJ; Feelders RA; van Aken MO; Lamberts SW; van der Lely AJ; Krenning EP
    Pituitary; 2006; 9(3):243-8. PubMed ID: 17001462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 mlBG scintimaging in neural crest tumors.
    Limouris GS; Giannakopoulos V; Stavraka A; Toubanakis N; Vlahos L
    Anticancer Res; 1997; 17(3B):1589-92. PubMed ID: 9179199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.
    Todorović-Tirnanić M; Kaemmerer D; Prasad V; Hommann M; Baum RP
    Recent Results Cancer Res; 2013; 194():487-96. PubMed ID: 22918778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
    Behr TM; Béhé MP
    Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
    Kwekkeboom DJ; Lamberts SW; Habbema JD; Krenning EP
    J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
    Gabriel M; Decristoforo C; Donnemiller E; Ulmer H; Watfah Rychlinski C; Mather SJ; Moncayo R
    J Nucl Med; 2003 May; 44(5):708-16. PubMed ID: 12732671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preferential localization of regional metastases from gastroenteropancreatic endocrine tumors with somatostatin-receptor scintigraphy.
    MacGillivray DC; Mumtaz MA; Kurtzman SH; Spencer RP; Weiner RE; Malchoff CD
    Arch Surg; 1996 Dec; 131(12):1338-42. PubMed ID: 8956777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery.
    Arslan N; Ilgan S; Yuksel D; Serdengecti M; Bulakbasi N; Ugur O; Ozguven MA
    Clin Nucl Med; 2001 Aug; 26(8):683-8. PubMed ID: 11452174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Role of somatostatin analogs in the treatment of neuroendocrine tumours].
    Cuccurullo V; Cascini GL; Rambaldi PF; Mansi L
    Minerva Endocrinol; 2001 Sep; 26(3):135-43. PubMed ID: 11753236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours.
    Savelli G; Lucignani G; Seregni E; Marchianò A; Serafini G; Aliberti G; Villano C; Maccauro M; Bombardieri E
    Nucl Med Commun; 2004 May; 25(5):445-9. PubMed ID: 15100502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radioguided surgery in neuroendocrine tumors using Ga-68-labeled somatostatin analogs: a pilot study.
    Kaemmerer D; Prasad V; Daffner W; Haugvik SP; Senftleben S; Baum RP; Hommann M
    Clin Nucl Med; 2012 Feb; 37(2):142-7. PubMed ID: 22228336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incremental diagnostic value and impact on patient management of somatostatin receptor scintigraphy with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors.
    Usmani S; Khan HA; Abdulla M; Ahmed N; abu Huda F; Marafi F; al Kandari F; al Mohannadi S; al Nafisi N
    Med Princ Pract; 2011; 20(4):356-61. PubMed ID: 21576997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen.
    Adams S; Baum RP; Hertel A; Schumm-Dräger PM; Usadel KH; Hör G
    Nucl Med Commun; 1998 Jul; 19(7):641-7. PubMed ID: 9853344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors.
    Ezziddin S; Logvinski T; Yong-Hing C; Ahmadzadehfar H; Fischer HP; Palmedo H; Bucerius J; Reinhardt MJ; Biersack HJ
    J Nucl Med; 2006 Feb; 47(2):223-33. PubMed ID: 16455627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.